The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Shares plunge more than 24% in early trading 2025 revenue forecast misses expectations, prior view CEO Bancel says to reduce 2025 cash costs by $1 bln Jan 13 (Reuters) - Moderna (MRNA.O), opens ...

Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year. Moderna said it expects 2025 revenue to range between $1.5 ...

Moderna (MRNA) anticipates milestones across 10 prioritized programs, including up to three potential 2025 approvals and six registrational data readouts. Published first on TheFly – the ...

Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...

Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory ...

Moderna has lowered 2025 revenue guidance after a tough 2024 coronavirus vaccination season. However, the company aims to launch 10 new products over the next few years -- and that could lead to ...

REUTERS/DADO RUVIC/ILLUSTRATION/FILE PHOTO Moderna logo and stock graph are seen displayed in this illustration in May 2022. Moderna cut its 2025 sales forecast by $1 billion today, hurt by a slow ...